search
Back to results

Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section

Primary Purpose

Opioid Misuse

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CPMRx
Sponsored by
Jessica Morgan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Opioid Misuse focused on measuring opioid misuse, mobile application, cesarean section

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is a female adult between the ages of 18-50 years
  • Patient is undergoing cesarean section procedure at Temple University Hospital
  • Patient is able and willing to provide informed consent
  • Patient has insurance that will cover cost of prescription drugs or is able to pay out-of-pocket
  • Patient has their own smart mobile phone (>80% of the target population owns a mobile phone)

Exclusion Criteria:

  • Patient with contraindications to opioid medications, NSAIDs, or acetaminophen (including but not limited to allergy, intolerance, inability to swallow pills, etc.)
  • Patient is unable to take tablets or tolerate oral intake
  • Patient has a diagnosis of acute or chronic pain disorder
  • Patient has used an opioid within the past 12 months
  • Patient is non-English speaking
  • Patient is unable to provide consent
  • Patient is currently incarcerated

Sites / Locations

  • Temple University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

No Intervention

Experimental

No Intervention

Arm Label

Mobile App + BP

BP

Mobile App Only

Control

Arm Description

Patients use a mobile application in addition to electronic monitoring blister packs for pain medications.

Patients' pain medication is in electronic monitoring blister packs.

Patients use a mobile application.

Outcomes

Primary Outcome Measures

Morphine Milligram Equivalents (MME) Used
Total number of Morphine Milligram Equivalents (MME) used during the postoperative period.

Secondary Outcome Measures

Pain Scores
Average pain scores by day, measured on a sliding scale from 0 (none) to 10 (worst pain)

Full Information

First Posted
July 13, 2022
Last Updated
August 17, 2023
Sponsor
Jessica Morgan
Collaborators
Temple University
search

1. Study Identification

Unique Protocol Identification Number
NCT05461196
Brief Title
Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section
Official Title
Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 12, 2021 (Actual)
Primary Completion Date
August 1, 2022 (Actual)
Study Completion Date
August 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jessica Morgan
Collaborators
Temple University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: Cesarean delivery is one of the most common obstetric procedures experienced among women who are pregnant.1 Women with Cesarean deliveries have a higher rate of peripartum opioid prescriptions and persistent opioid use compared to those with vaginal deliveries.2 Since 2002, prescription opioid use and misuse has significantly increased among women, including those who are pregnant, showing over 31% increase in past-month heroin use among women of childbearing age.3 This indicates the importance of focusing on maternal population for prescribed opioid medication management during the immediate postpartum period to prevent long-term persistent opioid misuse. Few evidence-based approaches are available to remotely manage prescription opioid use post-discharge.4 Recent advances in mobile technology have made it possible to monitor behavior and maintain communication in near real-time, long after patients are discharged from their surgical procedures.5-7 Using a virtual platform via use of mobile technology offers potential for sustainable implementation of a behavioral intervention and patient-provider communication even during the COVID-19 pandemic.8 Continuous Precision Medicine (CPM™; Research Triangle Park, NC) has developed a mobile app to overcome these barriers for tracking pain and pain medication use among post-surgery patients and tested the logistical and technological feasibility in postpartum patients at Temple OB/GYN. Collectively, our team brings expertise and collaborations between Temple University Hospital, RTI International, and CPM for the following Specific Aims: Aim 1: To examine the preliminary impact of the CPM mobile app to reduce the use of opioids among women post-Cesarean surgery Hypothesis 1: Patients using the CPM application will use fewer Morphine Milligram Equivalents (MME) compared to the blister package group. Aim 2: To establish correlates of pain medication use among women post-Cesarean surgery to estimate the appropriate recommendable dosages per model. Hypothesis 2: Structural and intermediary social determinants such as younger age, lower socioeconomic status, violence and trauma exposure, substance use disorder, and mental and physical health issues will be associated with more opioid medication use.
Detailed Description
Experimental Design: A randomized pilot trial will be conducted with 100 females at Temple University Hospital immediately post-Cesarean delivery. The women will be randomized (1:1) to either: using the CPM mobile app and electronic monitoring blister packs (experimental group) or to blister packs only (control group). The primary outcome is Morphine Milligram Equivalents (MME). Secondary outcomes will be delay to dosages and pain scores. We will examine whether a mobile application found feasible by post-surgery patients and healthcare professionals has a preliminary impact on opioid medication use among women who are immediately postpartum and had Cesarean surgery. The CPM application provides patients with a detailed prescription regimen, allows a patient to report dose-by-dose pain scores, and helps the patient consider whether a dose is needed via gamification, and creates usage traceability for clinicians to reduce over-prescription. Linear regression, including ANOVA and repeated mixed models will be used to compare groups on the primary continuous outcomes of daily MME during the 10-day period. The initial models will only include a term for study group. Variables that are statistically significant (<0.05) by univariate analyses, as well as theoretically important covariates will be considered for inclusion in adjusted analyses to improve their precision. Pain scores as a secondary continuous outcome will be evaluated using regression models for linear and non-linear mixed effect models. If no significant differences in these outcomes were detected, resampling Bootstrap method will be used to estimate effect sizes (i.e., Cohen's d) and its 95% confidence intervals, considering potential non-normal distribution of data. Further, we will utilize structural equation modeling (SEM) for its greater flexibility and capacity of handling the structural relationship between measured variables and latent constructs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Misuse
Keywords
opioid misuse, mobile application, cesarean section

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mobile App + BP
Arm Type
Experimental
Arm Description
Patients use a mobile application in addition to electronic monitoring blister packs for pain medications.
Arm Title
BP
Arm Type
No Intervention
Arm Description
Patients' pain medication is in electronic monitoring blister packs.
Arm Title
Mobile App Only
Arm Type
Experimental
Arm Description
Patients use a mobile application.
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
CPMRx
Intervention Description
Patients use a mobile application to track pain medication usage and pain scores.
Primary Outcome Measure Information:
Title
Morphine Milligram Equivalents (MME) Used
Description
Total number of Morphine Milligram Equivalents (MME) used during the postoperative period.
Time Frame
First 7 days following discharge
Secondary Outcome Measure Information:
Title
Pain Scores
Description
Average pain scores by day, measured on a sliding scale from 0 (none) to 10 (worst pain)
Time Frame
Daily for 7 days following discharge

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is a female adult between the ages of 18-50 years Patient is undergoing cesarean section procedure at Temple University Hospital Patient is able and willing to provide informed consent Patient has insurance that will cover cost of prescription drugs or is able to pay out-of-pocket Patient has their own smart mobile phone (>80% of the target population owns a mobile phone) Exclusion Criteria: Patient with contraindications to opioid medications, NSAIDs, or acetaminophen (including but not limited to allergy, intolerance, inability to swallow pills, etc.) Patient is unable to take tablets or tolerate oral intake Patient has a diagnosis of acute or chronic pain disorder Patient has used an opioid within the past 12 months Patient is non-English speaking Patient is unable to provide consent Patient is currently incarcerated
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gail Herrine, MD
Organizational Affiliation
Temple University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Temple University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19122
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section

We'll reach out to this number within 24 hrs